Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension

Tomohito Kamada, Mutsuharu Hayashi, Wakaya Fujiwara, Daiji Yoshikawa, Daisuke Mukaide, Yoshinori Sugishita, Masataka Yoshinaga, Takehiro Itoh, Hiroatsu Yokoi, Junichi Ishii, Eiichi Watanabe, Yukio Ozaki, Hideo Izawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: The number of elderly patients with hypertension has been steadily increasing. However, there are limited data on the safety and efficacy of the new angiotensin type 1 receptor blocker (ARB) azilsartan in elderly patients with hypertension. We investigated the clinical efficacy and safety of azilsartan in this population. Methods: The study population comprised 56 ambulatory patients with essential hypertension. We evaluated the reduction in blood pressure and safety after 12 weeks of treatment with azilsartan in 29 hypertensive patients ≥65 years of age (aged group) in comparison with the findings in 27 patients <65 years of age (non-aged group). Results: Systolic blood pressure in the aged group declined significantly from 155 ± 18 mmHg at baseline to 138 ± 11 mmHg after 12 weeks of treatment with azilsartan, and that in the non-aged group also declined significantly from 152 ± 20 mmHg at baseline to 142 ± 13 mmHg after 12 weeks of treatment with azilsartan. There were no significant differences in the magnitude of change in blood pressures from pre-treatment to post-treatment with azilsartan between the non-aged and aged groups. There were no changes in clinical laboratory findings, including serum levels of creatinine, potassium, lipids, and other metabolic variables, after 12 weeks of treatment with azilsartan in both groups. Conclusions: Our findings suggest that azilsartan is effective in lowering blood pressure in elderly patients and may be safe. Therefore, azilsartan could be a valuable option for treating hypertension in elderly and non-elderly patients.

Original languageEnglish
Pages (from-to)110-114
Number of pages5
JournalDrug and Chemical Toxicology
Volume40
Issue number1
DOIs
Publication statusPublished - 02-01-2017

Fingerprint

Angiotensin Receptor Antagonists
Blood pressure
Antihypertensive Agents
Hypertension
Safety
Blood Pressure
Clinical laboratories
Lipids
Potassium
Therapeutics
Blood Safety
Angiotensin II Type 1 Receptor Blockers
azilsartan
Population
Creatinine
Age Groups

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology
  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety

Cite this

Kamada, Tomohito ; Hayashi, Mutsuharu ; Fujiwara, Wakaya ; Yoshikawa, Daiji ; Mukaide, Daisuke ; Sugishita, Yoshinori ; Yoshinaga, Masataka ; Itoh, Takehiro ; Yokoi, Hiroatsu ; Ishii, Junichi ; Watanabe, Eiichi ; Ozaki, Yukio ; Izawa, Hideo. / Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension. In: Drug and Chemical Toxicology. 2017 ; Vol. 40, No. 1. pp. 110-114.
@article{33fd56ed20e84bb6ba1ce4295bd576c2,
title = "Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension",
abstract = "Objectives: The number of elderly patients with hypertension has been steadily increasing. However, there are limited data on the safety and efficacy of the new angiotensin type 1 receptor blocker (ARB) azilsartan in elderly patients with hypertension. We investigated the clinical efficacy and safety of azilsartan in this population. Methods: The study population comprised 56 ambulatory patients with essential hypertension. We evaluated the reduction in blood pressure and safety after 12 weeks of treatment with azilsartan in 29 hypertensive patients ≥65 years of age (aged group) in comparison with the findings in 27 patients <65 years of age (non-aged group). Results: Systolic blood pressure in the aged group declined significantly from 155 ± 18 mmHg at baseline to 138 ± 11 mmHg after 12 weeks of treatment with azilsartan, and that in the non-aged group also declined significantly from 152 ± 20 mmHg at baseline to 142 ± 13 mmHg after 12 weeks of treatment with azilsartan. There were no significant differences in the magnitude of change in blood pressures from pre-treatment to post-treatment with azilsartan between the non-aged and aged groups. There were no changes in clinical laboratory findings, including serum levels of creatinine, potassium, lipids, and other metabolic variables, after 12 weeks of treatment with azilsartan in both groups. Conclusions: Our findings suggest that azilsartan is effective in lowering blood pressure in elderly patients and may be safe. Therefore, azilsartan could be a valuable option for treating hypertension in elderly and non-elderly patients.",
author = "Tomohito Kamada and Mutsuharu Hayashi and Wakaya Fujiwara and Daiji Yoshikawa and Daisuke Mukaide and Yoshinori Sugishita and Masataka Yoshinaga and Takehiro Itoh and Hiroatsu Yokoi and Junichi Ishii and Eiichi Watanabe and Yukio Ozaki and Hideo Izawa",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/01480545.2016.1188301",
language = "English",
volume = "40",
pages = "110--114",
journal = "Drug and Chemical Toxicology",
issn = "0148-0545",
publisher = "Informa Healthcare",
number = "1",

}

Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension. / Kamada, Tomohito; Hayashi, Mutsuharu; Fujiwara, Wakaya; Yoshikawa, Daiji; Mukaide, Daisuke; Sugishita, Yoshinori; Yoshinaga, Masataka; Itoh, Takehiro; Yokoi, Hiroatsu; Ishii, Junichi; Watanabe, Eiichi; Ozaki, Yukio; Izawa, Hideo.

In: Drug and Chemical Toxicology, Vol. 40, No. 1, 02.01.2017, p. 110-114.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension

AU - Kamada, Tomohito

AU - Hayashi, Mutsuharu

AU - Fujiwara, Wakaya

AU - Yoshikawa, Daiji

AU - Mukaide, Daisuke

AU - Sugishita, Yoshinori

AU - Yoshinaga, Masataka

AU - Itoh, Takehiro

AU - Yokoi, Hiroatsu

AU - Ishii, Junichi

AU - Watanabe, Eiichi

AU - Ozaki, Yukio

AU - Izawa, Hideo

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Objectives: The number of elderly patients with hypertension has been steadily increasing. However, there are limited data on the safety and efficacy of the new angiotensin type 1 receptor blocker (ARB) azilsartan in elderly patients with hypertension. We investigated the clinical efficacy and safety of azilsartan in this population. Methods: The study population comprised 56 ambulatory patients with essential hypertension. We evaluated the reduction in blood pressure and safety after 12 weeks of treatment with azilsartan in 29 hypertensive patients ≥65 years of age (aged group) in comparison with the findings in 27 patients <65 years of age (non-aged group). Results: Systolic blood pressure in the aged group declined significantly from 155 ± 18 mmHg at baseline to 138 ± 11 mmHg after 12 weeks of treatment with azilsartan, and that in the non-aged group also declined significantly from 152 ± 20 mmHg at baseline to 142 ± 13 mmHg after 12 weeks of treatment with azilsartan. There were no significant differences in the magnitude of change in blood pressures from pre-treatment to post-treatment with azilsartan between the non-aged and aged groups. There were no changes in clinical laboratory findings, including serum levels of creatinine, potassium, lipids, and other metabolic variables, after 12 weeks of treatment with azilsartan in both groups. Conclusions: Our findings suggest that azilsartan is effective in lowering blood pressure in elderly patients and may be safe. Therefore, azilsartan could be a valuable option for treating hypertension in elderly and non-elderly patients.

AB - Objectives: The number of elderly patients with hypertension has been steadily increasing. However, there are limited data on the safety and efficacy of the new angiotensin type 1 receptor blocker (ARB) azilsartan in elderly patients with hypertension. We investigated the clinical efficacy and safety of azilsartan in this population. Methods: The study population comprised 56 ambulatory patients with essential hypertension. We evaluated the reduction in blood pressure and safety after 12 weeks of treatment with azilsartan in 29 hypertensive patients ≥65 years of age (aged group) in comparison with the findings in 27 patients <65 years of age (non-aged group). Results: Systolic blood pressure in the aged group declined significantly from 155 ± 18 mmHg at baseline to 138 ± 11 mmHg after 12 weeks of treatment with azilsartan, and that in the non-aged group also declined significantly from 152 ± 20 mmHg at baseline to 142 ± 13 mmHg after 12 weeks of treatment with azilsartan. There were no significant differences in the magnitude of change in blood pressures from pre-treatment to post-treatment with azilsartan between the non-aged and aged groups. There were no changes in clinical laboratory findings, including serum levels of creatinine, potassium, lipids, and other metabolic variables, after 12 weeks of treatment with azilsartan in both groups. Conclusions: Our findings suggest that azilsartan is effective in lowering blood pressure in elderly patients and may be safe. Therefore, azilsartan could be a valuable option for treating hypertension in elderly and non-elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=84978484077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978484077&partnerID=8YFLogxK

U2 - 10.1080/01480545.2016.1188301

DO - 10.1080/01480545.2016.1188301

M3 - Article

C2 - 27424785

AN - SCOPUS:84978484077

VL - 40

SP - 110

EP - 114

JO - Drug and Chemical Toxicology

JF - Drug and Chemical Toxicology

SN - 0148-0545

IS - 1

ER -